Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07428616 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorStudy sites: 17 to 19Eligibility criteria expanded, about 20 wordsShow 1 more changeShow less
Eligibility criteria expanded, about 20 words
MinorTrial sites expanded: 12 → 17 locationsv7
MinorSite details revised at 1 of 12 sitesv6
MinorTrial sites expanded: 6 → 12 locationsv5
MinorTrial sites expanded: 3 → 6 locationsStart date changed from estimate of May 31, 2026 to May 21, 2026v4Show 1 more changeShow less
Start date changed from estimate of May 31, 2026 to May 21, 2026
NotableRecruitment openedSite details revised at 3 of 3 sitesv3Show 1 more changeShow less
Site details revised at 3 of 3 sites
MinorTrial sites expanded: 0 → 3 locationsPrimary completion date: Feb 2028 to Feb 29, 2028 · Completion date: Sep 2029 to Sep 30, 2029 · Start date: May 2026 to May 31, 2026v2Show 3 more changesShow less
Primary completion date: Feb 2028 to Feb 29, 2028
Completion date: Sep 2029 to Sep 30, 2029
Start date: May 2026 to May 31, 2026
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.